Clinical Trials Logo

Clinical Trial Summary

The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with Philadelphia positive (Ph+)ALL, whether this treatment is better tolerated, and whether subsequent combination therapy with imatinib and chemotherapy of approximately a 1 year duration is tolerable and effective with respect to maintaining remissions.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Leukemia
  • Leukemia, Lymphoid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Lymphoid Blastic Phase of Chronic Myeloid Leukemia
  • Philadelphia Positive Acute Lymphoblastic Leukemia
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT number NCT00199186
Study type Interventional
Source Johann Wolfgang Goethe University Hospitals
Contact Oliver G Ottmann, M.D.
Phone ++49-69-6301-0
Email ottmann@em.uni-frankfurt.de
Status Recruiting
Phase Phase 2
Start date March 2002

See also
  Status Clinical Trial Phase
Completed NCT03821727 - SCT in Ph Positive Acute Lymphoblastic Leukemia
Completed NCT01724879 - Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) Phase 2
Recruiting NCT04260022 - Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Phase 1
Completed NCT01914484 - Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia Phase 1/Phase 2